持続的腎代替療法(CRRT)の世界市場予測(~2026年):製品別(使い捨て用品(ヘモフィルター、血液ライン)、機械、透析液、腎代替療法)、モダリティ別(SCUF、CVVH、CVVHD、CVVHDF)、患者別(成人、小児、新生児)

◆英語タイトル:Continuous Renal Replacement Therapy (CRRT) Market by Product (Disposables (Hemofilters, Bloodlines), Machine, Dialysates, Renal Replacement fluids), Modality (SCUF, CVVH, CVVHD, CVVHDF), Patient (Adult, Pediatrics, Neonates) - Global Forecasts to 2026
◆商品コード:MD3842
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年6月22日
◆ページ数:176
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は持続的腎代替療法(CRRT)の世界市場規模が2021年12億ドルから2026年17億ドルまで、年平均7.3%成長すると予想しています。本書では、世界の持続的腎代替療法(CRRT)市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(透析液・補液、使い捨て用品、CRRTシステム)分析、モダリティ別(連続静脈-静脈血液濾過、連続静脈-静脈血液濾過、連続静脈-静脈血液透析、低速連続限外濾過)分析、年齢層別(成人、小児・新生児)分析、地域別分析、競争状況、企業情報などを整理しました。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・持続的腎代替療法(CRRT)の世界市場規模:製品別(透析液・補液、使い捨て用品、CRRTシステム)
・持続的腎代替療法(CRRT)の世界市場規模:モダリティ別(連続静脈-静脈血液濾過、連続静脈-静脈血液濾過、連続静脈-静脈血液透析、低速連続限外濾過)
・持続的腎代替療法(CRRT)の世界市場規模:年齢層別(成人、小児・新生児)
・持続的腎代替療法(CRRT)の世界市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global continuous renal replacement therapymarket size is projected to reach USD 1.7billion by 2026 from USD 1.2billion in 2021, at a CAGR of 7.3% during the forecast period.”
Factors such as rise in the incidence of AKI and rising emphasis on effective renal replacement therapy among ICU patients are factors boosting the demand for CRRT system and disposables. Moreover, the initiatives undertaken by governments to increase the awareness about CRRT therapy along with the increase in the launch of advanced CRRT system in the market, are anticipated to boost the demand for continuous renal replacement therapy during the forecast period.

“The recent COVID-19 global pandemic has also impacted thecontinuous renal replacement therapy market.”
The surge in the number of COVID cases, along with the rise in its severity rate, is likely to create a potential increase in the incidence of kidney damage. This makes AKI the next emerging healthcare concern after respiratory tract infections among patients with COVID-19.Due to the pandemic, the demand for renal replacement fluids has increased significantly worldwide. The demand for RRT among patients with COVID-19 has increased fivefold in comparison to the historical US populations (4.9% as of 2020 VS. 0.9% earlier) (Source: American Society of Nephrology, 2021). According to an article published by the International Society of Nephrology 2020, countries such as China and Italy reported AKI rates as high as 29%. The early initiation of continuous renal replacement therapy (CRRT) is an important step to curbing the rising incidence of AKI due to the COVID-19 infection. However, owing to the rapid rise in the demand by healthcare systems, HD and PD exist as an alternative dialysis treatment in ICUs, which can have a negative impact on the growth of the CRRT market during this period.

“The dialysate and replacement fluid segmentto capture the largest share in continuous renal replacement therapymarket, by product, during the forecast period.”
Thedialysate and replacement fluidsegment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the significant rise in demand for CRRT in the treatment of hemodynamically unstable patients, the increased number of manufacturers offering dialysate and replacement fluids for renal replacement therapy, and the strong presence of players in the market.

“The CVVHDF segment to witness highest growth rate in continuous renal replacement therapy market, by modality in 2021.”
The CVVHDF modality segment is anticipated to witness the highest growth rate during the forecast period. The growing preference of CVVHDF modality among a nephrologist and critical care physician, and the advantages such as better clearance of medium-sized solutes as compared to hemodialysis (owing to the combination of hemofiltration with the continuous HD procedure), proper acid-base balance without additional intervention, and a significant reduction in CRRT-related phosphate depletion area likely to play strong role in supporting the growth of the segment in the coming years.

“The Adultssegment accounted for the largest share of thecontinuous renal replacement therapy, by age group, in 2021.”
The rapidly growing cases of adult acute renal disease injury across the globe and the rising number of hospital admission among youth adults are playing a critical role in increasing the adoption of CRRT among adult age group population. Moreover,increasing frequency of aggressive surgical and medical interventions among adults, and the increasing the risk of developing AKI and further contributing to the market growth.

“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The continuous renal replacement therapymarket is segmented into five major regions, namely, North America, Europe, AsiaPacific, Latin America, and Middle East & Africa.Increase in the awareness of continuous renal replacement therapy, increasing healthcare expenditures, increasing patient population, rising sepsis incidence, increasing prevalence of hypertension & diabetes (major causes of AKI), the high use of CRRT in Australia and Japan, improving healthcare expenditure on renal diseases, and increasing accessibility to CRRT for AKI treatment.

Breakdown of supply-side primary interviews:
• By Company Type:Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
• By Designation:C-level: 26%, D-level: 30%, and Others: 44%
• By Region:North America: 40.4%, Europe: 28.0%, APAC: 19.0%, Latin America: 7.7%, and the Middle East & Africa: 5.0%

The major players operatinginthe continuous renal replacement therapymarket are Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland),Medtronic plc (Ireland), Medica S.p.A. (Italy), Medical Components, Inc. (US), Medites Pharma spol. s.r.o. (Czech Republic), SWS Hemodialysis Care Co., Ltd. (China), Ningbo Tianyi Medical Devices Co., Ltd. (China),Nipro Corporation (Japan), and Anjue Medical Equipment Co., Ltd. (China),

Research Coverage:
This report studies the continuous renal replacement therapymarket based on the product, modality, age group and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions(and the respective countries in these regions).

Key Benefits of Buying the Report:
This report focuses on various levels of analysis—industry trends, marketshareof top players, and company profiles, which together formbasic views and analyze the competitive landscape, emerging segments of the continuous renal replacement therapymarket, and high-growth regions and their drivers, restraints, opportunities, and challenges.The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the marketandgarner greater market shares.

【レポートの目次】

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 YEARS CONSIDERED FOR THE STUDY 27
1.4 CURRENCY USED FOR THE STUDY 27
1.5 MAJOR MARKET STAKEHOLDERS 27
1.6 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
FIGURE 1 RESEARCH DESIGN 29
2.1.1 SECONDARY DATA 30
2.1.1.1 Secondary sources 31
2.1.2 PRIMARY DATA 31
FIGURE 2 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT
THERAPY MARKET 32
2.2 MARKET ESTIMATION METHODOLOGY 32
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 33
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 33
2.2.2 USAGE-BASED MARKET ESTIMATION 34
FIGURE 4 ESTIMATION OF CRRT PROCEDURES 34
FIGURE 5 MARKET SIZE ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BASED ON PRODUCT UTILIZATION METHODOLOGY 35
FIGURE 6 MARKET SIZE ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BASED ON REVENUE MAPPING METHODOLOGY 35
2.2.3 PRIMARY RESEARCH VALIDATION 36
2.3 DATA TRIANGULATION 36
FIGURE 7 DATA TRIANGULATION METHODOLOGY 37
2.4 RESEARCH ASSUMPTIONS 37
2.5 RESEARCH LIMITATIONS 38
3 EXECUTIVE SUMMARY 39
FIGURE 8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 39
FIGURE 9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY,
2021 VS. 2026 (USD MILLION) 40
FIGURE 10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021 VS. 2026 (USD MILLION) 40
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE CONTINUOUS RENAL
REPLACEMENT THERAPY MARKET 41
4 PREMIUM INSIGHTS 43
4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW 43
FIGURE 12 RISING PREVALENCE OF AKI AND GROWING AWARENESS ABOUT CRRT TO DRIVE MARKET GROWTH 43
4.2 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SHARE, BY AGE GROUP, 2021 44
FIGURE 13 ADULTS SEGMENT TO DOMINATE THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET IN 2021 44
4.3 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT AND COUNTRY 45
FIGURE 14 DIALYSATES AND REPLACEMENT FLUIDS ACCOUNT FOR THE LARGEST SHARE OF THE CRRT PRODUCTS MARKET IN THE APAC 45
FIGURE 15 APAC MARKET TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026) 46
5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47
5.2.1 DRIVERS 48
5.2.1.1 Increasing incidence of acute kidney injury (AKI) 48
FIGURE 17 GLOBAL INCIDENCE OF AKI, 2010 VS. 2015 VS. 2020 48
TABLE 1 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2019 VS. 2050 49
5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis 49
FIGURE 18 IMPACT OF ICU-ACQUIRED AKI IN THE US 50
5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification 50
5.2.1.4 Technological advancements and new product launches 51
5.2.1.5 Growing prevalence of diabetes and hypertension 51
FIGURE 19 TOP 5 COUNTRIES WITH CHILDREN AND ADOLESCENTS WITH TYPE I DIABETES, 2019 52
5.2.2 RESTRAINTS 52
5.2.2.1 Stringent regulatory guidelines in North America 52
5.2.2.2 High procedural cost of CRRT 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emerging markets in APAC and RoW 53
5.2.3.2 Increasing applications of CRRT 53
5.2.3.2.1 Evolution of CRRT from a simple renal replacement treatment to multi-organ support therapy 53
5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines 54

5.2.3.3 Ongoing research to establish the safety and efficacy profile of CRRT 54
5.2.3.4 Development of CRRT systems for pediatric patients 54
5.2.3.4.1 The CARPEDIEM Project 55
5.2.3.5 Untapped growth opportunities in North America 55
5.2.4 CHALLENGES 55
5.2.4.1 High complexity of CRRT 55
5.2.4.2 Lack of standard treatment guidelines in developing nations 56
5.2.4.3 Shortage of trained ICU professionals in developing nations 56
5.2.4.4 Poor reimbursement scenario in developing countries 56
5.2.4.5 Lack of awareness about the benefits of CRRT 57
5.3 GLOBAL REGULATORY LANDSCAPE 57
5.3.1 NORTH AMERICA 57
5.3.2 EUROPE 57
5.3.3 ASIA PACIFIC 58
5.3.3.1 India 58
5.3.3.2 China 58
5.3.3.3 Japan 58
5.3.3.4 South Korea 58
5.3.4 REST OF THE WORLD (ROW) 58
5.3.4.1 Brazil 58
5.3.4.2 Argentina 59
5.4 GLOBAL REIMBURSEMENT SCENARIO 59
5.4.1 NORTH AMERICA 59
5.4.2 EUROPE 59
5.4.3 ASIA PACIFIC 60
5.4.4 JAPAN 60
5.4.5 REST OF THE WORLD (ROW) 61
5.4.5.1 Brazil 61
5.4.5.2 Central America and the Caribbean 61
5.5 COVID-19 IMPACT ON THE CRRT MARKET 61
FIGURE 20 US: COVID-19 HOSPITALIZATION DATA FOR SPECIALIZED MEDICAL CONDITIONS IN ADULTS (AS OF APRIL 11, 2020) 62
5.6 VALUE CHAIN ANALYSIS 63
FIGURE 21 VALUE CHAIN OF THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 63
5.7 ECOSYSTEM COVERAGE 64
5.8 PRICING TREND ANALYSIS 64
TABLE 2 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD) 64
5.9 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 3 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.9.1 THREAT FROM NEW ENTRANTS 65
FIGURE 22 THREAT FROM NEW ENTRANTS 66
5.9.2 THREAT FROM SUBSTITUTES 66
FIGURE 23 THREAT FROM SUBSTITUTES 66
5.9.3 BARGAINING POWER OF SUPPLIERS 66
FIGURE 24 BARGAINING POWER OF SUPPLIERS 67
5.9.4 BARGAINING POWER OF BUYERS 67
FIGURE 25 BARGAINING POWER OF BUYERS 67
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 68
FIGURE 26 INTENSITY OF COMPETITIVE RIVALRY 68
6 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT 69
6.1 INTRODUCTION 70
TABLE 4 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 70
6.2 DIALYSATES & REPLACEMENT FLUIDS 70
6.2.1 RISING DEMAND FOR DIALYSATES HAS SUPPORTED MARKET GROWTH 70
TABLE 5 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY MODALITY,
2019–2026 (USD MILLION) 71
TABLE 6 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY AGE GROUP,
2019–2026 (USD MILLION) 71
TABLE 7 DIALYSATES & REPLACEMENT FLUIDS MARKET, BY REGION,
2019–2026 (USD MILLION) 72
6.3 DISPOSABLES 72
TABLE 8 DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 72
TABLE 9 DISPOSABLES MARKET, BY MODALITY, 2019–2026 (USD MILLION) 73
TABLE 10 DISPOSABLES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION) 73
TABLE 11 DISPOSABLES MARKET, BY REGION, 2019–2026 (USD MILLION) 73
6.3.1 HEMOFILTERS 74
6.3.1.1 Hemofilters are widely adopted during CRRT procedures for the treatment of AKI 74
TABLE 12 HEMOFILTERS MARKET, BY REGION, 2019–2026 (USD MILLION) 74
TABLE 13 HEMOFILTERS MARKET, BY MODALITY, 2019–2026 (USD MILLION) 74
TABLE 14 HEMOFILTERS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION) 75
6.3.2 BLOODLINE SETS & TUBES 75
6.3.2.1 Established players are focusing on strengthening their bloodline sets and tubes product lines 75
TABLE 15 BLOODLINE SETS & TUBES MARKET, BY REGION, 2019–2026 (USD MILLION) 76
TABLE 16 BLOODLINE SETS & TUBES MARKET, BY MODALITY,
2019–2026 (USD MILLION) 76
TABLE 17 BLOODLINE SETS & TUBES MARKET, BY AGE GROUP,
2019–2026 (USD MILLION) 76
6.3.3 OTHER DISPOSABLES 77
TABLE 18 OTHER DISPOSABLES MARKET, BY REGION, 2019–2026 (USD MILLION) 77
TABLE 19 OTHER DISPOSABLES MARKET, BY MODALITY, 2019–2026 (USD MILLION) 77
TABLE 20 OTHER DISPOSABLES MARKET, BY AGE GROUP, 2019–2026 (USD MILLION) 78
6.4 CRRT SYSTEMS 78
6.4.1 INTRODUCTION OF ADVANCED PRODUCTS TO DRIVE THE DEMAND
FOR CRRT SYSTEMS 78
TABLE 21 CRRT SYSTEMS MARKET, BY MODALITY, 2019–2026 (USD MILLION) 79
TABLE 22 CRRT SYSTEMS MARKET, BY AGE GROUP, 2019–2026 (USD MILLION) 79
TABLE 23 CRRT SYSTEMS MARKET BY REGION, 2019–2026 (USD MILLION) 79
7 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY MODALITY 80
7.1 INTRODUCTION 81
TABLE 24 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019–2026 (USD MILLION) 81
7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION 82
7.2.1 WIDESPREAD ADOPTION OF CVVH IN THE TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET GROWTH 82
TABLE 25 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY REGION,
2019–2026 (USD MILLION) 82
7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION 83
7.3.1 CVVHDF IS USED IN PATIENTS WITH CONGESTIVE HEART FAILURE 83
TABLE 26 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY REGION, 2019–2026 (USD MILLION) 83
7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS 83
7.4.1 THIS THERAPY IS MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES AS COMPARED TO OTHER CRRT MODALITIES 83
TABLE 27 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY REGION,
2019–2026 (USD MILLION) 84
7.5 SLOW CONTINUOUS ULTRAFILTRATION 84
7.5.1 SCUF DOES NOT USE DIALYSATES OR REPLACEMENT FLUIDS FOR THE REMOVAL OF EXCESS FLUID FROM THE BLOODSTREAM 84
TABLE 28 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY REGION,
2019–2026 (USD MILLION) 85
8 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP 86
8.1 INTRODUCTION 87
TABLE 29 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019–2026 (USD MILLION) 87
8.2 ADULTS 87
8.2.1 ADULTS HOLD THE LARGEST SHARE OF THE MARKET BY AGE GROUP 87
TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS,
BY REGION, 2019–2026 (USD MILLION) 88
8.3 PEDIATRICS & NEONATES 88
8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO AID THE MARKET GROWTH DURING THE FORECAST PERIOD 88
TABLE 31 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS & NEONATES, BY REGION, 2019–2026 (USD MILLION) 89
9 GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION 90
9.1 INTRODUCTION 91
TABLE 32 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION,
2019–2026 (USD MILLION) 91
9.2 EUROPE 92
FIGURE 27 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT 92
TABLE 33 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 93
TABLE 34 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 93
TABLE 35 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 93
TABLE 36 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY MODALITY, 2019–2026 (USD MILLION) 94
TABLE 37 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY AGE GROUP, 2019–2026 (USD MILLION) 94
9.2.1 GERMANY 95
9.2.1.1 Germany is the largest market for continuous renal replacement therapy in Europe 95
TABLE 38 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 95
TABLE 39 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 95
9.2.2 UK 96
9.2.2.1 Rising number of sepsis cases in the UK to support market growth 96
TABLE 40 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 96
TABLE 41 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 97
9.2.3 FRANCE 97
9.2.3.1 France is the fastest-growing market for CRRT in Europe 97
TABLE 42 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 97
TABLE 43 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 98
9.2.4 ITALY 98
9.2.4.1 Government initiatives to promote the awareness of CRRT for renal care to drive market growth 98
TABLE 44 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 98
TABLE 45 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION 99
9.2.5 SPAIN 99
9.2.5.1 Favorable reimbursement scenario to favor market growth 99
TABLE 46 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 99
TABLE 47 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 100
9.2.6 REST OF EUROPE 100
TABLE 48 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 100
TABLE 49 ROE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 101
9.3 NORTH AMERICA 101
TABLE 50 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 101
TABLE 51 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 102
TABLE 52 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 102
TABLE 53 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY MODALITY, 2019–2026 (USD MILLION) 103
TABLE 54 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY AGE GROUP, 2019–2026 (USD MILLION) 103
9.3.1 US 103
9.3.1.1 Large number of AKI patients in the region to drive the market growth 103
TABLE 55 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 104
TABLE 56 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 105
9.3.2 CANADA 105
9.3.2.1 High cost of CRRT as compared to IHD is negatively impacting market growth in Canada 105
TABLE 57 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 106
TABLE 58 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 106
9.4 ASIA PACIFIC 106
FIGURE 28 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SNAPSHOT 107
TABLE 59 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 60 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 108
TABLE 61 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 62 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019–2026 (USD MILLION) 109
TABLE 63 APAC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019–2026 (USD MILLION) 109
9.4.1 JAPAN 109
9.4.1.1 Increasing use of CRRT to boost the market in Japan 109
TABLE 64 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 110
TABLE 65 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 110
9.4.2 CHINA 111
9.4.2.1 Increasing prevalence of ESRD and AKI to boost the
demand for CRRT 111
TABLE 66 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 111
TABLE 67 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 112
9.4.3 INDIA 112
9.4.3.1 Growing number of AKI patients and ICU admissions to support market growth 112
TABLE 68 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 113
TABLE 69 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 113
9.4.4 AUSTRALIA 113
9.4.4.1 The Australian government is taking various initiatives to increase the awareness of CRRT 113
TABLE 70 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 114
TABLE 71 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 114
9.4.5 SOUTH KOREA 114
9.4.5.1 The country is witnessing an increasing number of patients receiving CRRT for the treatment of AKI 114
TABLE 72 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 115
TABLE 73 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 115
9.4.6 REST OF ASIA PACIFIC 115
TABLE 74 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 116
TABLE 75 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 116
9.5 LATIN AMERICA 117
TABLE 76 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 117
TABLE 77 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 117
TABLE 78 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 118
TABLE 79 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY MODALITY, 2019–2026 (USD MILLION) 118
TABLE 80 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY AGE GROUP, 2019–2026 (USD MILLION) 119
9.5.1 BRAZIL 119
9.5.1.1 Brazil holds the largest share in the Latin American CRRT market 119
TABLE 81 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 119
TABLE 82 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 120
9.5.2 MEXICO 120
9.5.2.1 Large patient population and growing middle-class population to support market growth in Mexico 120
TABLE 83 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 120
TABLE 84 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 121
9.5.3 REST OF LATIN AMERICA 121
TABLE 85 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 121
TABLE 86 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 122
9.6 MIDDLE EAST & AFRICA 122
9.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN THE MARKET GROWTH IN THE REGION 122
TABLE 87 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 122
TABLE 88 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 89 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2019–2026 (USD MILLION) 123
TABLE 90 MEA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2019–2026 (USD MILLION) 124
10 COMPETITIVE LANDSCAPE 125
10.1 OVERVIEW 125
10.2 KEY PLAYER STRATEGIES 125
10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 126
FIGURE 29 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE CRRT MARKET 126
10.4 GLOBAL MARKET SHARE ANALYSIS (2020) 126
TABLE 91 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DEGREE OF COMPETITION 126
10.5 COMPETITIVE LEADERSHIP MAPPING 128
10.5.1 STARS 128
10.5.2 EMERGING LEADERS 128
10.5.3 PERVASIVE PLAYERS 128
10.5.4 PARTICIPANTS 128
FIGURE 30 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020 129

10.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020) 129
10.6.1 PROGRESSIVE COMPANIES 129
10.6.2 STARTING BLOCKS 130
10.6.3 RESPONSIVE COMPANIES 130
10.6.4 DYNAMIC COMPANIES 130
FIGURE 31 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2020 131
10.7 FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 131
10.7.1 PRODUCT AND GEOGRAPHICAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 131
TABLE 92 INDUSTRY FOOTPRINT OF COMPANIES 132
TABLE 93 REGIONAL FOOTPRINT OF COMPANIES 133
10.7.1.1 Continuous renal replacement therapy market: Product launches and regulatory approvals (January 2018 to May 2021) 134
TABLE 94 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 134
10.7.1.2 Continuous renal replacement therapy market: Deals
(January 2018 to May 2021) 135
TABLE 95 KEY DEALS 135
10.7.1.3 Continuous renal replacement therapy market: Other developments (January 2018 to May 2021) 136
TABLE 96 KEY OTHER DEVELOPMENTS 136
11 COMPANY PROFILES 137
11.1 MAJOR PLAYERS 137
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 BAXTER INTERNATIONAL INC. 137
TABLE 97 BAXTER INTERNATIONAL INC.: BUSINESS OVERVIEW 137
FIGURE 32 COMPANY SNAPSHOT: BAXTER INTERNATIONAL INC. 138
TABLE 98 BAXTER INTERNATIONAL INC.: PRODUCT OFFERINGS 138
11.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA 141
TABLE 99 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW 141
FIGURE 33 COMPANY SNAPSHOT: FRESENIUS MEDICAL CARE AG & CO. KGAA 142
TABLE 100 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS 143
11.1.3 NIKKISO CO., LTD. 145
TABLE 101 NIKKISO CO., LTD.: BUSINESS OVERVIEW 145
FIGURE 34 COMPANY SNAPSHOT: NIKKISO CO., LTD. 146
TABLE 102 NIKKISO CO., LTD.: PRODUCT OFFERINGS 147
11.1.4 B. BRAUN MELSUNGEN AG 148
TABLE 103 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW 148
FIGURE 35 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG 149
TABLE 104 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS 149
11.1.5 MEDTRONIC PLC 151
TABLE 105 MEDTRONIC PLC: BUSINESS OVERVIEW 151
FIGURE 36 COMPANY SNAPSHOT: MEDTRONIC PLC 152
TABLE 106 MEDTRONIC PLC: PRODUCT OFFERINGS 152
11.1.6 ASAHI KASEI CORPORATION 154
TABLE 107 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW 154
FIGURE 37 COMPANY SNAPSHOT: ASAHI KASEI CORPORATION 155
TABLE 108 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS 155
11.1.7 TORAY MEDICAL CO., LTD. 156
TABLE 109 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW 156
FIGURE 38 COMPANY SNAPSHOT: TORAY MEDICAL CO., LTD. 157
TABLE 110 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS 157
11.1.8 NIPRO CORPORATION 158
TABLE 111 NIPRO CORPORATION: BUSINESS OVERVIEW 158
FIGURE 39 COMPANY SNAPSHOT: NIPRO CORPORATION 158
TABLE 112 NIPRO CORPORATION: PRODUCT OFFERINGS 159
11.1.9 INFOMED SA 160
TABLE 113 INFOMED SA: BUSINESS OVERVIEW 160
TABLE 114 INFOMED SA: PRODUCT OFFERINGS 160
11.1.10 MEDICA SPA 162
TABLE 115 MEDICA SPA: BUSINESS OVERVIEW 162
11.1.10.2 Products offered 162
TABLE 116 MEDICA SPA: PRODUCT OFFERINGS 162
11.1.11 MEDITES PHARMA SPOL. S.R.O 164
TABLE 117 MEDITES PHARMA SPOL. S.R.O: BUSINESS OVERVIEW 164
TABLE 118 MEDITES PHARMA SPOL. S.R.O: PRODUCT OFFERINGS 164
11.1.12 MEDICAL COMPONENTS, INC. 165
TABLE 119 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW 165
TABLE 120 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS 165
11.1.13 SWS HEMODIALYSIS CARE CO. LTD. 167
TABLE 121 SWS HEMODIALYSIS CARE CO. LTD.: BUSINESS OVERVIEW 167
TABLE 122 SWS HEMODIALYSIS CARE CO. LTD.: PRODUCT OFFERINGS 167
11.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD. 169
TABLE 123 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW 169
TABLE 124 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS 169
11.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD. 170
TABLE 125 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW 170
TABLE 126 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS 170
11.2 EMERGING PLAYERS 171
11.2.1 KIMAL 171
11.2.2 JIANGXI SANXIN MEDTEC CO., LTD. 171
11.2.3 ALLMED MEDICAL PRODUCTS CO., LTD. 172
11.2.4 DIALCO MEDICAL INC. 172
11.2.5 BROWNDOVE HEALTHCARE PVT. LTD. 173
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 174
12.1 DISCUSSION GUIDE 174
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 178
12.3 AVAILABLE CUSTOMIZATIONS 180
12.4 RELATED REPORTS 180
12.5 AUTHOR DETAILS 181



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[持続的腎代替療法(CRRT)の世界市場予測(~2026年):製品別(使い捨て用品(ヘモフィルター、血液ライン)、機械、透析液、腎代替療法)、モダリティ別(SCUF、CVVH、CVVHD、CVVHDF)、患者別(成人、小児、新生児)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆